Overview

Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to estimate the effect of preoperative gefitinib on the complete pathological response rate in primary estrogen receptor negative breast cancer at the time of surgery.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Gefitinib